Cytometric analysis of cell suspension generated by cavitron ultrasonic surgical aspirator in pediatric brain tumors.


Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
May 2019
Historique:
received: 09 01 2019
accepted: 23 02 2019
pubmed: 4 3 2019
medline: 29 8 2019
entrez: 4 3 2019
Statut: ppublish

Résumé

The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. CUSA specimens obtained from 19 pediatric patients with brain tumors were investigated. Flow and mass cytometry methods were applied to analyze the composition of material collected using the CUSA. Cell suspensions were prepared from CUSA aspirates. Then sample viability was assessed by conventional flow cytometry and subsequently stained with a panel of 31 metal-labeled antibodies. Viability assessment was performed using conventional flow cytometry. Viability of cells in the acquired samples was below 50% in 16 of 19 cases. A mass cytometry investigation and subsequent analysis enabled us to discriminate brain tumor cells from contaminating leukocytes, whose proportions varied across the specimens. The addition of the viability marker cisplatin directly into the mass cytometry panel gave the means to selecting viable cells only for subsequent analyses. The proportion of non-viable cells was higher among tumor cells compared leukocytes. When the analysis of the tumor cell immunophenotype is performed with markers for determining viability, the expression of the investigated markers can be evaluated. Suitable markers can be selected by high-throughput methods, such as mass cytometry, and those that are diagnostically relevant can be investigated using flow cytometry, which is more flexible in terms of time.

Identifiants

pubmed: 30827009
doi: 10.1007/s11060-019-03135-w
pii: 10.1007/s11060-019-03135-w
doi:

Substances chimiques

Biomarkers, Tumor 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-25

Subventions

Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 15-26588A
Organisme : Univerzita Karlova v Praze
ID : UNCE 204012
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LO1604

Références

Mol Cancer. 2006 Dec 02;5:67
pubmed: 17140455
Anal Chem. 2009 Aug 15;81(16):6813-22
pubmed: 19601617
Leuk Res. 2011 Aug;35(8):1111-3
pubmed: 21497902
Trends Immunol. 2012 Jul;33(7):323-32
pubmed: 22476049
Exp Cell Res. 2013 Feb 15;319(4):517-28
pubmed: 23201135
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Nat Neurosci. 2013 Oct;16(10):1373-82
pubmed: 23995067
Cancers (Basel). 2013 Apr 03;5(2):357-71
pubmed: 24216981
Cytometry B Clin Cytom. 2014 Jul;86(4):288-91
pubmed: 25057519
Int J Oncol. 2015 Jul;47(1):91-6
pubmed: 25955568
Oncotarget. 2015 Nov 17;6(36):38881-900
pubmed: 26497209
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
CNS Oncol. 2016 Jul;5(3):159-73
pubmed: 27230973
J Neurooncol. 2017 Jan;131(2):233-244
pubmed: 27770278
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
J Neurooncol. 2017 Sep;134(3):505-512
pubmed: 28233083
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
Biophys Rev. 2016 Mar;8(1):5-9
pubmed: 28510148
Oncoimmunology. 2017 Nov 6;7(2):e1391973
pubmed: 29308321
Brain Tumor Pathol. 2018 Apr;35(2):81-89
pubmed: 29569163
J Cancer Res Clin Oncol. 2018 Jul;144(7):1227-1237
pubmed: 29696364
Cancer Res. 2018 Aug 15;78(16):4745-4759
pubmed: 29930101
Clin Cancer Res. 2019 Apr 1;25(7):2042-2048
pubmed: 30446589
World Neurosurg. 2018 Dec 26;:null
pubmed: 30593958
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006
pubmed: 30602457
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Cytometry A. 2019 Mar;95(3):290-301
pubmed: 30729665
Oncogene. 2019 Feb 11;:null
pubmed: 30742096
Clin Neurosurg. 1983;31:497-505
pubmed: 6680087

Auteurs

Martina Vaskova (M)

CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. martina.vaskova@lfmotol.cuni.cz.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. martina.vaskova@lfmotol.cuni.cz.

Michal Tichy (M)

Department of Neurosurgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Josef Zamecnik (J)

Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Petr Liby (P)

Department of Neurosurgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Daniela Kuzilkova (D)

CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Ales Vicha (A)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Jan Hrabeta (J)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Tomas Kalina (T)

CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Jan Stary (J)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Ondrej Hrusak (O)

CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH